… compared with EGFR-TKI alone in both mutated and wild-type EGFR women with non–small
cell lung cancer… trial to investigate the tolerance and efficacy of fulvestrant combined with an …

… [35], median PFS in the gefitinib plus anlotinib group was … plus erlotinib group compared
with the placebo plus erlotinib … , whose efficacy is lower compared with a third generation TKI. …

… randomized, phase-2 study comparing the efficacy and tolerability of erlotinib 100 mg/d vs. …
or third-line treatment of patients with EGFR wild-type advanced nonsmall-cell lung cancer (…

… or erlotinib represented the most common therapeutic options. … the efficacy and safety of
fruquintinib in patients with advanced, pre-… , describes an advantage of fruquintinib compared to …

… , to evaluate the treatment efficacy and associated prognostic … LM indicated a worse outcome
compared to those without LM… LM as a third-line or further therapy, when compared with …

… the efficacy and safety of dacomitinib versus gefitinib as a first… dacomitinib and gefitinib),
second- and third-line treatment, … difference in effectiveness between erlotinib and gefitinib (and …

… efficacy and safety of afatinib compared with chemotherapy. … Only a minority of the patients
received third-line treatment in … patients with advanced non-small-cell lung cancer previously …

… -tumor activity in patients with advanced non-small cell lung … the efficacy and safety of anlotinib
maintenance therapy in … anlotinib for third-line-and-beyond treatment of advanced NSCLC …

… is effective in treating non-small cell lung cancer (NSCLC), … The difference between our and
their results may be due to … the second-line, third-line or higher-line treatment after EGFR TKI …

… disease and in the first-line palliative setting, PD-L1 status has been shown to be predictive
of the efficacy of … In all the studies comparing erlotinib to chemotherapy in older patients with …